Testosterone, TRT and Fertility: Can You Treat Low T Without Losing Sperm?
For a younger man with low testosterone, one of the most important questions should come before the prescription is written:
Do you want children now—or might you want them later?
That question can completely change the treatment strategy.
Traditional testosterone replacement therapy can improve testosterone levels, libido, body composition, energy, sexual function, and other symptoms in appropriately selected men.
But testosterone also suppresses the hormonal signals that the testicles need to produce sperm.
For some men, sperm counts decline.
For others, they fall dramatically.
And some men become azoospermic—meaning there are no sperm detectable in the ejaculate.
That does not mean every man taking testosterone becomes permanently infertile. In most men, sperm production eventually recovers after testosterone is stopped.
But recovery can take months—and occasionally much longer.
For a man who hopes to have children, that distinction matters.
Why Testosterone Can Reduce Sperm Production
The testes perform two major hormonal jobs.
First, Leydig cells produce testosterone.
Second, the seminiferous tubules produce sperm.
Those processes depend heavily on signals coming from the brain.
The hypothalamus releases GnRH, which stimulates the pituitary gland to release:
LH — luteinizing hormone
FSH — follicle-stimulating hormone
LH stimulates Leydig cells to produce testosterone inside the testicle.
FSH acts primarily on Sertoli cells and supports spermatogenesis.
The testosterone concentration inside the testicle—called intratesticular testosterone—is dramatically higher than the testosterone concentration measured in the bloodstream.
That very high local testosterone environment is important for normal sperm production.
Understanding the difference between total testosterone, free testosterone and SHBG is also important when evaluating low T.
When testosterone is administered from outside the body, serum testosterone increases.
The brain sees that testosterone and reduces GnRH, LH, and FSH production.
Serum testosterone may look excellent.
But the testes may receive very little LH or FSH stimulation.
And intratesticular testosterone can collapse.
That is why a man can have a serum testosterone of 800 or 1,000 ng/dL while producing very few—or no—sperm.
This isn’t theoretical.
In a landmark physiologic study, men receiving weekly testosterone enanthate without hCG experienced approximately a 94% decline in intratesticular testosterone after gonadotropins were suppressed.
How Common Is Azoospermia on Testosterone?
We have surprisingly good data because testosterone has actually been studied as a potential male contraceptive.
In one World Health Organization trial, 271 healthy fertile men were given testosterone enanthate 200 mg weekly.
After six months:
65% became azoospermic.
The average time to azoospermia was about four months.
A larger multinational analysis found that after six months of weekly testosterone:
approximately 97–99% of men suppressed below 5 million sperm/mL
approximately 96–98% suppressed below 3 million/mL
approximately 67% of non-Asian men and 89% of Asian men became azoospermic
So complete azoospermia is not inevitable.
But profound suppression of sperm production is extremely common.
That leads to an important misconception.
TRT is not reliable birth control.
Some men remain oligospermic rather than azoospermic.
Pregnancies can still occur.
So testosterone should never be used as contraception.
At the same time, a man trying to conceive should never assume his fertility is preserved simply because ejaculation and sexual function remain normal.
The only way to know what is happening with sperm production is to evaluate it.
What Happens When Testosterone Is Stopped?
Fortunately, testosterone-induced suppression of spermatogenesis is usually reversible.
But recovery isn’t instantaneous.
An integrated analysis of 1,549 men enrolled in hormonal male-contraception studies found that after stopping treatment, the probability of recovering to a sperm concentration of at least 20 million/mL was approximately:
67% by 6 months
90% by 12 months
96% by 16 months
essentially 100% by 24 months in that controlled study population
The median recovery time was approximately 3.4 months.
However, those were predominantly healthy men enrolled in controlled trials.
They are not necessarily equivalent to a 42-year-old man with baseline hypogonadism who has been taking testosterone for five years.
In clinical practice, recovery can be less predictable.
Age and duration of prior testosterone exposure appear to matter.
One infertility-clinic study of men recovering from testosterone-associated infertility found that increasing age and longer testosterone exposure were associated with slower sperm recovery.
Among previously azoospermic men, only about 65% achieved a total motile sperm count above 5 million within 12 months despite stopping testosterone and receiving fertility-directed therapy.
So the appropriate counseling is not:
“Don’t worry. Your fertility will definitely come right back.”
It is:
Most men recover sperm production, but the timing is variable and recovery to previous baseline fertility cannot be guaranteed.
Before Starting TRT: Ask About Fertility
This is why a good testosterone evaluation should involve more than simply checking a testosterone level.
For a younger man, I want to know:
Does he want children?
When?
Has he already had children?
Has he ever had a semen analysis?
Has he experienced infertility before?
What are his LH and FSH levels?
Is his hypogonadism primary or secondary?
Is there testicular atrophy?
Has he used testosterone or anabolic steroids previously?
Is his partner’s reproductive timeline relevant?
The answers can dramatically change the treatment plan.
The 2024 AUA/ASRM Male Infertility Guideline states that clinicians should not prescribe exogenous testosterone to men interested in current or future fertility, particularly when family building is planned in the near term.
The Endocrine Society similarly recommends against initiating testosterone therapy in men planning fertility in the near future.
Option 1: TRT Alone
TRT alone is usually the simplest strategy for a hypogonadal man who has completed his family and has no meaningful fertility concerns.
Treatment may include:
injectable testosterone
transdermal testosterone
oral testosterone
nasal testosterone
other FDA-approved formulations
But longer-acting systemic testosterone generally suppresses LH and FSH.
Injection frequency also affects testosterone peaks, troughs, and overall treatment quality.
For a man who wants future fertility, that suppression should be discussed before treatment begins.
If future fertility matters but pregnancy is years away, sperm banking before starting therapy can also be considered.
Option 2: TRT Plus hCG
This is where the physiology becomes particularly interesting.
Human chorionic gonadotropin—or hCG—acts very similarly to LH.
It binds the LH receptor on Leydig cells and stimulates testosterone production inside the testicle.
The idea is straightforward:
TRT provides systemic testosterone.
hCG provides continued LH-like stimulation to the testes.
The goal is to prevent intratesticular testosterone from collapsing.
The Intratesticular Testosterone Study
One of the most important studies examined 29 healthy men receiving testosterone enanthate.
Participants also received:
placebo
125 IU hCG every other day
250 IU every other day
or 500 IU every other day
Without hCG, intratesticular testosterone fell approximately 94%.
But with hCG:
125 IU every other day maintained intratesticular testosterone at approximately 25% below baseline
250 IU every other day maintained it at approximately 7% below baseline
500 IU every other day actually increased intratesticular testosterone to approximately 26% above baseline
Importantly, LH and FSH remained profoundly suppressed.
The hCG was essentially replacing the missing LH signal directly at the testicle.
That study measured intratesticular testosterone—not pregnancy outcomes.
But it provided the physiologic foundation for using low-dose hCG alongside TRT.
Does TRT Plus hCG Actually Preserve Sperm?
There are some compelling human data.
One frequently cited study followed 26 hypogonadal men treated with testosterone plus 500 IU hCG every other day.
Their average baseline sperm concentration was approximately 35 million/mL.
During treatment:
serum testosterone increased substantially
semen volume was maintained
sperm concentration was maintained
motility was maintained
no patient became azoospermic
Some men were followed for longer than one year.
Pregnancies also occurred during treatment.
That is a very interesting finding because it demonstrates that suppression of serum LH and FSH does not automatically mean spermatogenesis must disappear if sufficient intratesticular stimulation is maintained.
But there is an important caveat.
This was a small observational study.
Twenty-six patients is not enough to establish that TRT plus hCG reliably preserves fertility in every man.
That is why current AUA/ASRM guidance acknowledges studies showing preservation of spermatogenesis with hCG added to testosterone but concludes that the literature remains too limited to routinely recommend this strategy for men actively pursuing pregnancy.
That distinction matters.
TRT + hCG may reduce the risk of fertility suppression. It should not be presented as a fertility guarantee.
What Might a Fertility-Preserving hCG Dose Look Like?
Different protocols exist.
The physiologic study discussed above examined:
125–500 IU every other day.
The semen-preservation study used:
500 IU every other day.
In clinical practice, lower maintenance doses are also commonly used, such as several hundred IU two or three times per week, depending on the patient’s goals and response.
There is no universally established dose that guarantees preserved fertility.
The appropriate dose may depend on:
baseline testosterone
baseline semen analysis
testicular size and function
fertility timeline
estradiol response
concurrent testosterone dose
LH/FSH physiology
previous testosterone exposure
And for a man actively trying to conceive, I would generally think differently than I would for a 30-year-old who may want children five years from now.
If Pregnancy Is the Goal Right Now, hCG-Based Therapy May Make More Sense
For a man who currently wants fertility, avoiding exogenous testosterone entirely is often the cleaner strategy.
One option is hCG monotherapy.
Instead of replacing testosterone from outside the body, hCG stimulates the testes to produce testosterone themselves.
That accomplishes something traditional TRT cannot:
It raises systemic testosterone while maintaining intratesticular stimulation.
The AUA/ASRM guideline specifically states that hCG, SERMs, aromatase inhibitors, or combinations of these treatments may be used in infertile men with low serum testosterone.
How Does hCG Monotherapy Work?
hCG acts as an LH analogue.
It stimulates Leydig cells to produce testosterone.
This can raise:
serum testosterone
intratesticular testosterone
while avoiding the complete shutdown created by exogenous testosterone.
However, hCG does not directly replace FSH.
That distinction becomes important in men with severe gonadotropin deficiency.
Some men will produce sperm with hCG alone.
Others eventually require additional FSH stimulation.
Does hCG Alone Produce Sperm?
Yes—particularly when enough baseline testicular and FSH function remains.
A classic study evaluated 22 men with isolated hypogonadotropic hypogonadism.
All achieved normal testosterone concentrations using hCG.
During hCG monotherapy:
14 of 22 men developed sperm in the ejaculate.
Among men attempting conception, 7 of 13 successfully achieved conception, resulting in eight pregnancies.
Interestingly, sperm concentrations at conception were below 10 million/mL in all but one successful case.
That illustrates another important fertility concept:
A semen analysis is not a binary fertile/infertile test.
Pregnancy can occur at sperm concentrations considerably below traditional laboratory reference ranges.
When hCG Alone Isn’t Enough
Sperm production requires both:
very high intratesticular testosterone
and
FSH/Sertoli-cell stimulation.
hCG supplies the LH-like signal.
But some men—particularly those with profound gonadotropin deficiency, very small testes, or prolonged suppression—may eventually require FSH.
A fertility-directed regimen might therefore progress from:
hCG
to
hCG + recombinant FSH
depending on semen-analysis response.
A 2024 retrospective study examined 77 men with previous testosterone exposure treated with:
3,000 IU hCG + 75 IU FSH three times weekly.
Approximately 74% demonstrated improvement in sperm concentration.
Interestingly, improvement occurred at a similar rate even among a subset who continued testosterone during gonadotropin treatment, although this remains retrospective evidence rather than a randomized fertility trial.
What About Men Who Are Already Azoospermic From TRT?
This is a common referral scenario.
A man starts testosterone.
He feels better.
Several years later, he and his partner decide they want children.
A semen analysis shows:
zero sperm.
That can be frightening.
But testosterone-associated azoospermia is often recoverable.
One study evaluated 49 men with testosterone-associated azoospermia or severe oligospermia below 1 million sperm/mL.
They were treated with high-dose hCG—3,000 IU every other day—plus an additional fertility medication such as clomiphene, tamoxifen, anastrozole, or recombinant FSH.
Spermatogenesis returned or markedly improved in 47 of 49 men.
Average time to recovery:
4.6 months.
Average first recovered sperm concentration:
22.6 million/mL.
Again, that does not mean every patient will recover that quickly.
But testosterone-induced azoospermia should not automatically be viewed as permanent sterility.
What Should the Semen Analysis Look Like?
When fertility actually matters, testosterone bloodwork is not enough.
A semen analysis provides direct information about reproductive potential.
Important measurements include:
Semen volume
How much ejaculate is produced.
Sperm concentration
How many sperm are present per milliliter.
Total sperm count
Concentration multiplied by semen volume.
Motility
The percentage of sperm that are moving.
Progressive motility
The percentage moving effectively forward.
Morphology
The percentage with normal structural appearance.
Total motile sperm count
One of the most clinically useful fertility measures.
It incorporates semen volume, sperm concentration, and motility.
For men preserving fertility during hormonal therapy, I am often more interested in the trend over time than whether a single number falls above or below a reference cutoff.
Establish a Baseline Before Treatment
If fertility is important, one of the most useful things a man can do before starting hormonal therapy is obtain a baseline semen analysis.
That tells us what we are trying to preserve.
Without one, consider this scenario:
A man starts TRT.
A year later his sperm concentration is 8 million/mL.
Did testosterone reduce his count from 60 million?
Or was his baseline already 9 million?
Those are very different clinical situations.
Baseline information matters.
For men with substantial future fertility concerns, sperm cryopreservation before treatment can also be considered.
How Often Should Semen Analysis Be Repeated?
There is no single schedule appropriate for every patient.
Remember that a complete cycle of human spermatogenesis takes roughly 74 days, with additional time required for epididymal maturation and transport.
That means semen changes lag behind hormonal changes.
Checking a semen analysis two weeks after changing therapy generally tells you very little.
For a man actively trying to preserve or restore fertility, repeating semen testing approximately every 2–3 months often provides more useful information.
The timeline should still be individualized according to reproductive urgency.
What About Clomiphene or Enclomiphene?
Another strategy is to stimulate the man’s own hypothalamic-pituitary-gonadal axis rather than give testosterone.
Selective estrogen receptor modulators such as clomiphene reduce estrogen-mediated negative feedback at the hypothalamus and pituitary.
That can increase:
LH
FSH
endogenous testosterone
Because gonadotropins remain active, these treatments generally do not suppress spermatogenesis the way exogenous testosterone does.
Enclomiphene—the trans-isomer of clomiphene—has also been studied as a testosterone-raising strategy and has demonstrated preservation of sperm concentration in clinical trials.
These options can be attractive for selected younger men with secondary hypogonadism.
But they are not interchangeable with TRT.
The testosterone response, symptom response, estradiol response, and tolerability can differ substantially between men.
And they are much less likely to work when the underlying problem is primary testicular failure with already elevated LH and FSH.
What About Oral Testosterone Such as Kyzatrex?
This is one of the more interesting unanswered questions.
Kyzatrex is oral testosterone undecanoate.
Unlike a long-acting injection or pellet, oral testosterone produces a much shorter testosterone exposure profile.
That raises an intriguing possibility:
Could shorter testosterone exposure produce less complete suppression of LH and FSH—and therefore preserve more spermatogenesis?
There is some reason to think it might.
A recent review in Nature Reviews Urology noted that newer short-acting testosterone formulations—including oral testosterone undecanoate and nasal testosterone—may produce incomplete suppression of the hypothalamic-pituitary-gonadal axis and therefore may partially preserve spermatogenesis.
But “may preserve” and “proven fertility-safe” are very different statements.
Early Oral Testosterone Fertility Data
Researchers have been interested in this question for decades.
In a small early study of oral testosterone undecanoate, seven healthy men received 80 mg three times daily for approximately 10–12 weeks.
Only one of seven became azoospermic.
The others demonstrated either modest sperm suppression or essentially preserved sperm counts.
Researchers theorized that the relatively short testosterone exposure after each dose did not suppress gonadotropins continuously enough to shut down spermatogenesis completely.
But seven patients from an older formulation and dosing strategy cannot establish clinical fertility safety for modern oral testosterone.
More Recent Oral Testosterone Data
A prospective pilot study presented in 2024 specifically evaluated semen parameters in hypogonadal men receiving oral testosterone undecanoate.
The investigators looked at:
sperm concentration
motility
morphology
LH
FSH
testosterone
The study reflects growing interest in whether short-acting oral testosterone behaves differently from conventional TRT with respect to fertility.
But the authors themselves characterize the subject as understudied, and the available evidence remains far smaller than the evidence establishing fertility suppression with conventional exogenous testosterone.
There is also retrospective evidence from men with isolated hypogonadotropic hypogonadism.
In a study of 107 men, patients receiving oral testosterone undecanoate plus hCG were compared with those receiving hCG alone.
Adding oral testosterone normalized serum testosterone more rapidly.
Importantly, researchers found no significant difference in sperm appearance, sperm concentration, or time to sperm-production milestones between the groups.Again, these were men with hypogonadotropic hypogonadism receiving concurrent hCG—not typical men receiving Kyzatrex monotherapy.
So I would not tell a fertility-focused patient:
“Oral testosterone doesn’t suppress fertility.”
The evidence does not support that statement yet.
A better interpretation is:
Short-acting oral testosterone may suppress the reproductive axis less completely than long-acting TRT in some men, but we do not yet have sufficient fertility data to consider Kyzatrex reliably fertility-preserving.
That is a very important difference.
The Fertility Timeline Changes the Treatment
When I evaluate a younger man with low testosterone, I think about fertility in three broad categories.
Trying to conceive now
Exogenous testosterone is generally not my first choice.
Strategies may include:
hCG
hCG + FSH when necessary
clomiphene or enclomiphene in selected men
correction of reversible contributors
formal male-infertility evaluation when indicated
A baseline semen analysis is extremely useful.
Wants children in the next several years
This becomes more individualized.
Possibilities can include:
fertility-preserving endogenous testosterone stimulation
sperm banking
carefully selected hCG-containing approaches
periodic semen analysis
TRT plus hCG may sometimes be discussed, but patients should understand that preservation of fertility is not guaranteed.
Family complete
If fertility is no longer a consideration, conventional TRT becomes a much simpler discussion.
Primary Versus Secondary Hypogonadism Matters
Another reason men should not simply receive testosterone after one low blood test:
Low testosterone is not one disease.
Consider two men.
Man A
Testosterone: 230
LH: 2
FSH: 3
His testes may still be capable of producing testosterone and sperm if appropriately stimulated.
Man B
Testosterone: 230
LH: 18
FSH: 22
His pituitary is already sending a very strong signal.
The testes simply aren’t responding normally.
Giving hCG to these two men may produce very different results.
That is why LH and FSH should often be part of the evaluation before choosing therapy.
Fertility Preservation Requires More Than Adding hCG
I sometimes see hCG discussed almost like fertility insurance:
“Just add hCG to your testosterone and you’re covered.”
The data are more nuanced than that.
hCG can maintain intratesticular testosterone.
Small studies suggest TRT + hCG can preserve semen parameters in some men.
But:
baseline fertility varies
responses to testosterone vary
FSH remains suppressed during TRT
hCG does not directly replace FSH
not every man responds the same way
long-term pregnancy data remain limited
For a man who may want children someday, TRT + hCG can be a reasonable discussion.
For a man whose partner is actively undergoing IVF next month, the threshold for relying on that strategy should be very different.
The Bigger Point
Treating low testosterone in a 34-year-old man should not be approached exactly the same way as treating low testosterone in a 64-year-old man who has completed his family.
The laboratory number may be identical.
The treatment decision may not be.
Good testosterone care means understanding the man’s:
symptoms
testosterone physiology
LH and FSH
testicular function
semen parameters
fertility goals
fertility timeline
treatment preferences
TRT is an excellent treatment for many men.
hCG can be an extremely useful tool, either by itself or with TRT.
And fertility can frequently be preserved—or even restored.
But the strategy should be intentional.
The question isn’t simply:
“How do we raise testosterone?”
It is:
“How do we improve testosterone while protecting the things this man may still need his testes to do?”
That is a much better question.
Sadly, we see a significant number of new patients who were started on TRT elsewhere and never told it may affect their fertility.
Considering Testosterone Treatment but Still Want Children?
If you have symptoms of low testosterone but fertility matters now—or may matter later—the treatment plan should account for both.
At Fit & Fine Health, testosterone therapy is approached as part of a broader men’s health evaluation rather than as a one-size-fits-all prescription.
That may include evaluation of:
total and free testosterone
SHBG
LH and FSH
estradiol
prolactin
metabolic health
fertility goals
semen analysis when appropriate
Depending on the situation, options may include conventional TRT, hCG-based therapy, fertility-preserving testosterone strategies, or referral for more advanced reproductive treatment.
Dr. David Hall, MD, CWC
Board-Certified Urologist
Men’s Health & Metabolic Optimization
Fit & Fine Health
This article is educational and does not replace individualized medical evaluation. Fertility treatment should be tailored to the patient’s hormonal physiology, semen parameters, reproductive timeline, and the reproductive health of both partners.